Cassiopea announces that SIX has informed it that trading of its shares is suspended pending completion of the registration of the newly created shares
Cassiopea SpA, a specialty pharmaceutical company developing and preparing to commercialize prescription drugs with novel mechanisms of action (MOA) to address long-standing and essential dermatological conditions, today announces that SIX has informed it that trading of Cassiopea shares is suspended pending completion of administrative procedures in conjunction with the Italian authorities and SIX in relation to the registration of the newly created shares.